Kenvue Reports Full Year and Fourth Quarter 2024 Results SKILLMAN, N.J. February 6, 2025 – Kenvue Inc. (NYSE: KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. "We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we enter 2025 as a more competitive company with stronger foundations," said Thibaut Mongon, Chief Executive Officer. "We remain focused on leveraging our increased brand inv ...

Neutrogena's new campaign highlights products from its award-winning Hydro Boost range, including the Water Gel. This commemorates Hydro Boost's 10th anniversary as one of the brand's top-selling facial moisturizers, which jumpstarted the hyaluronic acid ingredient category. On average, a jar of Neutrogena Hydro Boost Water Gel is sold every two seconds worldwide1. At just 21 years old, McRae has captivated audiences as a chart-topping artist and dancer.  Now, as she prepares to release her third album, So ...

In its upcoming report, Kenvue (KVUE) is predicted by Wall Street analysts to post quarterly earnings of $0.25 per share, reflecting a decline of 19.4% compared to the same period last year. Revenues are forecasted to be $3.77 billion, representing a year-over-year increase of 2.9%.The current level reflects a downward revision of 1.8% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial project ...

Kenvue (KVUE) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 6, 2025, might help the stock move higher if these key numbers are better than expe ...

Even with the recent bout of market volatility, 2024 has been a fantastic year for stocks. The S&P 500 index has delivered a dividend-adjusted total return of roughly 25% across this year's trading. Meanwhile, the more growth-heavy Nasdaq Composite index has delivered a total return of 30%.This year's performance has marked one of the most impressive annual bull runs in stock market history, and major indexes have managed to notch new highs at multiple points across the stretch. But while many stocks now tr ...

Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip stocks, BDC's, and REITs. I am a buy-and-hold investor who prefers quality over quantity and plans to supplement his retirement income ...

For the quarter ended September 2024, Kenvue (KVUE) reported revenue of $3.9 billion, down 0.4% over the same period last year. EPS came in at $0.28, compared to $0.31 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.92 billion, representing a surprise of -0.56%. The company delivered an EPS surprise of +3.70%, with the consensus EPS estimate being $0.27.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Financial Performance - Net sales decreased by 0.4% to $3.9 billion, with organic growth of 0.9% and a foreign currency headwind of 1.3%[1][3] - Gross profit margin expanded by 100 basis points to 58.5%, while adjusted gross profit margin increased by 130 basis points to 60.7%[6] - Operating income margin was 16.8%, down from 18.1% in the prior year, with adjusted operating income margin at 22.1%, down from 23.3%[7] - Diluted earnings per share were $0.20, compared to $0.23 in the prior year, and adjusted diluted earnings per share were $0.28, down from $0.31[9] - Net income for the three months ended September 29, 2024, was $383 million, compared to $438 million for the same period last year, a decrease of 12.6%[35] - The diluted net income per share for the three months ended September 29, 2024, was $0.20, down from $0.23 in the same period last year[35] - Net income was reported at $737 million, translating to a net income margin of 6.2%[56] Sales and Segment Performance - Volume decline was primarily driven by Skin Health and Beauty and Self Care, partially offset by growth in Essential Health[4] - The Self Care segment reported net sales of $1,625 million for the three months ended September 29, 2024, an increase of 0.7% from $1,613 million in the same period last year[46] - The Essential Health segment achieved net sales of $1,202 million for the three months ended September 29, 2024, reflecting a growth of 1.6% compared to $1,183 million last year[46] - The Skin Health and Beauty segment saw a decline in net sales to $1,072 million for the three months ended September 29, 2024, down 4.2% from $1,119 million in the same period last year[46] Cost and Expenses - The company incurred restructuring expenses of $31 million in the three months ended September 29, 2024, compared to no such expenses in the same period last year[35] - Adjusted operating income for the fiscal three months ended September 29, 2024, was $860 million, a decrease of 5.9% from $914 million in the prior year[47] - Depreciation and amortization expenses for the fiscal three months ended September 29, 2024, totaled $160 million[50] - Research and development expenses for the fiscal three months ended September 29, 2024, increased to $97 million from $78 million in the same period last year[67] Tax and Interest - The effective tax rate increased to 33.6% from 25.1% in the prior year, impacting net income[8] - The effective tax rate for the fiscal three months ended September 29, 2024, was 33.6%[62] - The adjusted effective tax rate (non-GAAP) for the fiscal nine months ended September 29, 2024, was 27.6%[62] - The company forecasts an effective tax rate for fiscal year 2024 between 28.5% and 29.0%[63] - Interest expense for the third quarter was $96 million[8] - Interest expense for the fiscal three months ended September 29, 2024, was $96 million[50] - The company reported interest expense of $283 million for the fiscal nine months ended September 29, 2024[56] Future Outlook - For 2024, the company expects net sales growth and organic growth toward the low end of its outlook of 1.0%-3.0% and 2.0%-4.0%, respectively[10] - Future outlook includes a focus on new product development and market expansion strategies[56] Cash Flow and Debt - Free cash flow (non-GAAP) for the fiscal nine months ended September 29, 2024, was $0.7 billion, down from $2.0 billion for the same period in 2023[65] - Cash and cash equivalents as of September 29, 2024, were $1.1 billion, down from $1.4 billion as of December 31, 2023[67] - Total debt increased to $8.7 billion as of September 29, 2024, compared to $8.3 billion as of December 31, 2023[67] - Net debt as of September 29, 2024, was $(7.6) billion, compared to $(6.9) billion as of December 31, 2023[67] Geographic Performance - North America net sales for the fiscal nine months ended September 29, 2024, were $5.737 billion, down from $5.848 billion in the same period last year[66] - Europe, Middle East, and Africa net sales for the fiscal three months ended September 29, 2024, increased to $913 million from $864 million in the same period last year[66] - Asia Pacific net sales for the fiscal nine months ended September 29, 2024, were $2.339 billion, slightly down from $2.357 billion in the same period last year[66]

Group 1 - Starboard Value has acquired a $1 billion stake in Pfizer and is now also involved with Kenvue, aiming to improve shareholder returns after a 10.5% loss since its spinoff from Johnson & Johnson in 2023 [1][2] - Kenvue owns several well-known healthcare brands, including Neutrogena, Tylenol, and Listerine, making it a significant player in the consumer healthcare market [3] - Kenvue's annual net sales growth from 2019 to 2022 was only 3.4%, compared to a market growth rate of 4.8%, and its organic growth rate in 2023 was just 5%, lower than management's guidance [4][5] Group 2 - Starboard plans to enhance Kenvue's marketing capabilities, particularly in its underperforming skin and beauty segment, to improve growth and market share [6][7] - If management adopts Starboard's suggestions, Kenvue's growth could align with competitors, potentially improving stock valuation and enabling capital returns to shareholders [7] - The market has responded positively to Starboard's involvement, but there is a risk of public clashes with management, similar to their situation with Pfizer [8][9] Group 3 - There is skepticism about whether Starboard can significantly boost Kenvue's growth, given the nature of its business, and while changes may help reduce losses, substantial earnings growth seems unlikely without major initiatives [11] - The situation remains fluid, and the potential for a stronger investment thesis exists if Starboard's proposals are effectively implemented [12]

Business: Kenvue is a consumer health company. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Self Care product categories include pain care; cough cold allergy; and "other self care." The Skin Health and Beauty segment's product categories include face and body care and hair, sun and others. The Essential Health segment's product categories include oral care, baby care and other essential health. Its differentiated portfolio of brands includes Tylenol, ...